2. Organisational profile

More detailed information about the Orion Group’s operations and operational scope can be found in section 'Orion' of this website.

2.1 Name of the organisation

Orion Corporation

2.2 Primary brands, products and/or services

Pharmaceuticals
Active pharmaceutical ingredients
Diagnostic tests

2.3 Operational structure of the organisation, including main divisions, operating companies, subsidiaries and joint ventures

 Proprietary Products:

• Patented prescription drugs for central nervous system diseases, oncology and critical care, Easyhaler pulmonary drugs

Specialty Products:

• Generic (off-patent) prescription products and self-care products
  

Animal Health:

• Veterinary medicines and products for pets and production animals

Fermion: 

• Active pharmaceutical ingredients

Orion Diagnostica: 

• Diagnostic test systems for healthcare service providers and industry
  

2.4 Location of organisation’s headquarters

Orionintie 1 A
FI-02200 Espoo, Finland

2.5 Number of countries where the organisation operates, and names of countries with either major operations or that are specifically relevant to the sustainability issues covered in the report

Finland
Headquarters and administration in Espoo
Pharmaceutical manufacturing in Espoo, Turku and Kuopio
Active pharmaceutical ingredient manufacturing in Hanko and Oulu (Fermion)
Diagnostics manufacturing in Espoo and Turku
Pharmaceutical research centres in Espoo and Turku
Marketing: Espoo, Turku, Kuopio, Oulu, Tampere

Outside Finland
Marketing subsidiaries in 20 countries in Europe
Liaison office in India
 

2.6 Nature of ownership and legal form

Orion Corporation is a public company whose shares are listed on NASDAQ OMX Helsinki. The company has approximately 55,000 shareholders, of which 53,000 are households. Households own a little over 50% of the entire stock.
Current and more information on the shareholder base is provided in section 'Investors' at this website.

2.7 Markets served

The Orion Group operates in the pharmaceutical and diagnostics markets. Customers in these sectors include healthcare providers and professionals, consumers and other pharmaceutical companies. In healthcare, customers primarily include specialist doctors and general practitioners, vets, pharmacies, hospitals, healthcare centres, clinics and laboratories and their supply organisations.

Orion’s products are available in more than a hundred countries. Finland is the main market area, contributing a little less than one-third of net sales. The share of Scandinavia and rest of Europe of the net sales is about 50 per cent, and North-America and rest of the world about 20 per cent.

Outside Europe, Orion operates by granting marketing licenses to its products to other pharmaceutical companies.

2.8 Scale of the reporting organisation

 The Group’s net sales in 2009 amounted to EUR 771.5 million. International operations account to about 70 per cent of net sales.

At the end of 2009, the Group had about 3,150 employees, of whom some 2,500 in Finland and 650 in the foreign marketing subsidiaries.

Net sales of the Orion Group by market area 2007-2009

Key figures for 2007−2009

2.9 Significant changes during the reporting period regarding size, structure, or ownership

Orion’s current operational structure has been in place since the demerger in the summer of 2006, when Orion Corporation started as a new company specialising in pharmaceuticals and diagnostics. Net sales for 2009 were approximately 20 per cent higher compared with the 2006 pro forma net sales.

The total number of employees has increased by some 130 employees since 2006. The most notable changes in the number of employees have taken place in the pharmaceuticals business where the number of Finnish employees has decreased, whereas the number of employees in the foreign marketing organisations has increased.

The ownership structure of the Orion has undergone significant changes, in particular in 2009. At the end of 2007, Orion Corporation had 36,500 shareholders and at the end of 2008, there were 43,100 shareholders. By the end of 2009, the number of shareholders had reached 54,300.